menu
    • menu

    Company profile for Prolong Pharmaceuticals

    NEW Drugs in Dev: 5
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Prolong Pharmaceuticals®, LLC (Prolong) is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated products that address unmet medical needs. Prolong is currently developing a portfolio of products intended to treat CNS, Hematology, and Respiratory Disorders.Prolong is dedicated to establishing innovative therapeutics for individuals with severe and life-threatening co...
    Prolong Pharmaceuticals®, LLC (Prolong) is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated products that address unmet medical needs. Prolong is currently developing a portfolio of products intended to treat CNS, Hematology, and Respiratory Disorders.Prolong is dedicated to establishing innovative therapeutics for individuals with severe and life-threatening conditions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Prolong PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Corporate Court, Suite B South Plainfield, NJ 07080
    Telephone
    Telephone
    (908) 444-4660
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://prolongpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Prolong Pharma To Unveil PP-007 Data For AIS At 2025 WSC Conf
    Prolong Pharma To Unveil PP-007 Data For AIS At 2025 WSC Conf

    20 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-20/prolong-pharmaceuticals-to-present-phase-12-data-from-hemera-1-for-pp-007-in-acute-ischemic-stroke

    PHARMIWEB
    20 Oct 2025
    Share Share
    Prolong Pharma to Present Data from HEMERA-1 for PP-007 in AIS
    Prolong Pharma to Present Data from HEMERA-1 for PP-007 in AIS

    05 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250205025519/en

    BUSINESSWIRE
    05 Feb 2025
    Share Share
    Prolong Pharma to Present PP-007 Data at Blood Substitutes Symposium
    Prolong Pharma to Present PP-007 Data at Blood Substitutes Symposium

    13 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241113025280/en

    BUSINESSWIRE
    13 Nov 2024
    Share Share
    FDA Grants Prolong Fast Track Designation for Stroke Therapy
    FDA Grants Prolong Fast Track Designation for Stroke Therapy

    30 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241030373967/en

    BUSINESSWIRE
    30 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search